SCHEMBL24979083

SCHEMBL24979083

CCc1c(C2CC2)nc2c(c1N)CCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 19/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
BPTF Q12830 1/20 0.46
BCHE P06276 14/20 0.40
GRIN1 Q05586 10/20 0.39
GRIN2A Q12879 10/20 0.39
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
TSHR P16473 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CACNB4 O00305 1/20 0.36
CACNA1A O00555 1/20 0.36
SLC22A2 O15244 1/20 0.36
SLC22A1 O15245 1/20 0.36
ABCC4 O15439 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNG3 O60359 1/20 0.36
CACNA1F O60840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30162178 1.00 ACHE (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL24978158 0.85 GAA (0.38) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL22021441 0.84 ACHE (0.46) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL22019776 0.83 KDM4E (0.33) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL22019725 0.79 CYP1A2 (0.33) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL22020006 0.79 TSHR (0.34) MAPK1MEN1KMT2AALDH1A1KDM4E
SCHEMBL24977971 0.79 CYP1A2 (0.31) MAPK1ALDH1A1KDM4ETSHRCYP1A2
SCHEMBL22010279 0.79 ACHE (0.50) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL30120755 0.79 ACHE (0.50) ACHEMAPK1MEN1KMT2ABPTF
SCHEMBL22019951 0.78 ACHE (0.53) ACHEMAPK1MEN1KMT2ABPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230031406-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230031406-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 ACHE 4177/4885MAPK1 1647/4885MEN1 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.